Seventy-one allograft recipients receiving voriconazole, in whom complete clinical, microbiologic and pharmacokinetic data were available, were studied to determine the efficacy of voriconazole in preventing fungal infections. The length of voriconazole therapy was 6-956 days (median 133). The total number of patient-days on voriconazole was 13 805 (B38 years). A total of 10 fungal infections were seen in patients on voriconazole (18% actuarial probability at 1 year): Candida glabrata
Introduction
Invasive fungal infections are a significant cause of morbidity and mortality in recipients of hematopoietic stem cell transplantation (HSCT). The majority of infections are caused by Candida and Aspergillus species, usually several weeks to months post-transplant. 1 The incidence of aspergillosis in transplant patients has been increasing, and mortality rates remain high. 2 Current evidence-based guidelines recommend 400 mg fluconazole daily after HSCT for the prevention of invasive yeast infections. 3 However, fluconazole has no activity against Aspergillus or the more recently recognized emerging non-Aspergillus mold infections. As a result, while many centers continue using fluconazole, a number of centers have broadened coverage with more potent antifungal drugs to prevent mold infections. 4 Emergence of resistant Candida infections has been reported with prolonged exposure to azole drugs, especially at non-lethal concentrations. 5 Voriconazole, an extended spectrum triazole agent, has excellent clinical activity in aspergillosis and has been shown to be particularly effective in the prevention of breakthrough fungal infections, especially in patients at high risk for aspergillosis. 6 It also has excellent in vitro activity against many Candida species, although the in vitro MIC90 (Minimum Inhibitory Concentration required to inhibit the growth of 90% of organisms) for Candida glabrata are higher than for other fluconazole-sensitive Candida species (0.5-1 versus 2). 7 Voriconazole has no activity against zygomycetes. Although voriconazole is not approved for empiric use in neutropenic fever, the reduction in breakthrough fungal infections seen in patients receiving the drug 8 makes it an attractive candidate for prevention of aspergillosis. A recent study has reported an association between successful therapeutic outcome in Aspergillus infections and sustaining voriconazole concentrations above the MIC; 9 suggesting the possible need for therapeutic drug monitoring.
While our standard antifungal prophylaxis for allograft recipients is itraconazole, 10 we switch to voriconazole when patients receive corticosteroids or have had a mold infection in the past. We have also implemented voriconazole therapeutic drug monitoring. 11 The purpose of this retrospective review was to determine the efficacy of voriconazole in preventing invasive fungal infections in our patient population and to find out if there was any correlation between drug levels and efficacy.
Patients and methods
Seventy-one adult allogeneic HSCT recipients with hematologic malignancies who received voriconazole posttransplant for at least 7 days, and in whom complete clinical, microbiological and pharmacokinetic data were available were studied. Fifty-four patients switched from itraconazole to voriconazole after starting corticosteroid therapy for acute or chronic graft-versus-host disease (GVHD). These patients had started itraconazole on the day of stem cell infusion. The remaining 17 patients received voriconazole from the day of stem cell infusion because of a prior history of suspected or confirmed aspergillosis.
Voriconazole was usually administered at the dose of 200 mg twice daily orally, and was continued until a month beyond discontinuation of all immunosuppression or development of a fungal infection requiring change in therapy. Steady-state trough blood levels of voriconazole were drawn before the morning dose and measured at least 5 days after the drug was initiated and measured as previously described. 11, 12 Although the period following stem cell transplantation includes the administration of many drugs metabolized by the cytochrome P450 system, there were no drugs given concomitantly that were known to change voriconazole disposition.
Patients underwent radiologic studies as clinically indicated. Sequential galactomannan testing was not performed. Patients were treated between January 2003 and May 2006. The retrospective review was approved by Northwestern University's institutional review board as part of a project evaluating outcome of allogeneic HSCT. Table 1 shows patient characteristics. The duration of prior itraconazole therapy in the 54 patients who switched from itraconazole to voriconazole was 1-161 days (median 14). The total duration of exposure to voriconazole was 13 805 patient-days (B38 years).
Results
Most patients received corticosteroids at some point in time while on voriconazole. The dose of steroids varied according to severity of GVHD, with the majority of patients (81%) receiving intravenous methylprednisolone. The maximum daily dose of corticosteroids was X2 mg/kg (median maximum daily dose 500 mg).
Ten microbiologically confirmed fungal infections were seen, six Candida and four Zygomycetes. Not a single case of aspergillosis was seen. Patients in whom the fungus was seen on bronchoalveolar lavage or endotracheal tube aspirate had lung infiltrates compromising pulmonary status, and no other known cause for the pulmonary infiltrates (compatible with possible to probable infection by the European Organization for Research and Treatment of Cancer criteria). Table 2 provides detailed information on the 10 cases. Concomitant bacteremia was seen in all six patients with candidiasis and in two of the patients with zygomycosis.
All the patients with candidiasis received caspofungin. The two candidiasis cases (Patients 1 and 4) in which the fungal infection was felt to have contributed died of polymicrobial sepsis. Clearance of Candida was demonstrated on repeat bronchoscopy in three patients (Patients 2, 3 and 6). As most patients had concomitant infections, attributable mortality could not be definitely established. Patients in whom death was felt to be at least partly due to the fungal infection were those in whom pulmonary infiltrates did not resolve (and indeed progressed), and in whom there was no other predominant cause of death.
Among the zygomycosis cases, patients 7 and 9 were treated with posaconazole, patient 8 received amphotericin B lipid complex, and patient 10 received liposomal ampotericin B. Patient 8 had received prophylactic itraconazole for over 4 months before a change was made to voriconazole prophylaxis when signs and symptoms of sinusitis developed. Zygomycosis involving the sinuses was confirmed 7 days later. It is unlikely that voriconazole contributed to the development of zygomycosis in this case. Similarly, patient 10 had received itraconazole for almost 2.5 months before a change was made to voriconazole. Zygomycosis was diagnosed less than 3 weeks later, suggesting that the contribution of voriconazole therapy to zygomycosis in this case is debatable. Figures 1 and 2 show the actuarial probability of invasive fungal infections (18% at 1 year) and zygomycosis (7% at 1 year), respectively, from the initiation of voriconazole therapy. Table 3 shows plasma voriconazole trough levels. Excluding the four zygomycosis cases, all six candidiasis cases were seen among the 43 patients with voriconazole levels of p2 mg/ml and none among the 24 with levels of 42 mg/ml (P ¼ 0.061; Fisher's exact test). Including the four zygomycosis cases, the six candidiasis cases were seen among the 44 patients with voriconazole levels of p2 mg/ml and none among the 27 with levels of 42 mg/ml (P ¼ 0.049; Fisher's exact test).
Discussion
Our data show that voriconazole is effective in preventing Aspergillus infections in immunocompromised allogeneic HSCT recipients. While there is some breakthrough zygomycosis, the incidence appears to be low. The study also suggests that there may be a link between low plasma Voriconazole after allogeneic HSCT S Trifilio et al voriconazole levels and breakthrough infections with fungi that are otherwise susceptible to the drug, a relationship that requires exploration in a prospective study. The limitations of the data are their retrospective nature, a relatively small number of patients, and the lack of availability of MICs in the specific fungi isolated in patients. Table 3 Voriconazole levels Range (mg/ml) o0.2 to 6.97
Median (mg/ml)
1.04
Level range (mg/ml) The observed efficacy of voriconazole in preventing Aspergillus infections confirms the results reported by Siwek et al. 13 who found no cases of aspergillosis among 92 allogeneic HSCT recipients. Prophylactic fluconazole improves survival of HSCT recipients.
14 Since fluconazole has no activity against Aspergillus species, it is not unreasonable to expect that voriconazole would have similar benefit on survival because of its broader spectrum of activity. However, there are no randomized data to support or refute this hypothesis.
The overall incidence of zygomycosis in cancer patients appears to be increasing. 15, 16 However, there is a concern that prior voriconazole use predisposes to zygomycosis. 13, 17, 18 Our data appear to support the suggestion of breakthrough zygomycosis. However, we do not believe that it is a problem unique to voriconazole or one that is solely attributable to it. Two patients in this study (Patients 8 and 10; Table 2 ) had received prophylactic itraconazole for 122 and 63 days, respectively, before switching to voriconazole on account of GVHD requiring corticosteroids, and had been on voriconazole for only 7 and 17 days, respectively, before zygomycosis was diagnosed. Patient 8 had symptoms of sinusitis for a few days before the diagnosis being made, and patient 10 had pulmonary infiltrates for approximately a week before the diagnosis was made. This suggests that prior itraconazole therapy may have been responsible for the development of zygomycosis in two of the four patients. We have reported another case of breakthrough zygomycosis and aspergillosis on itraconazole prophylaxis. 19 Indeed, as Figure 3 (measured from the time of starting itraconazole in those who started it before switching to voriconazole, or from the time of starting voriconazole in those who did not receive itraconazole) shows, over 2.5 months of combined itraconazole/voriconazole therapy have elapsed before the first episode of zygomycosis occurs. This suggests that therapy/prophylaxis effective against aspergillosis may need to continue for several weeks before breakthrough zygomycosis becomes a risk.
After seeing the results of this analysis, we have streamlined our antifungal prophylaxis practice in allogeneic HSCT recipients by eliminating itraconazole entirely and administering voriconazole from the beginning in all patients. The recent approval of posaconazole raises the intriguing possibility of alternating prophylaxis between voriconazole and posaconazole every 1-2 months in patients who require prolonged broad-spectrum antifungal prophylaxis. The experience with itraconazole and voriconazole suggests that switching to posaconazole exclusively for prophylaxis may not be an optimum solution as other serious mycoses may emerge -and such an approach should ideally be undertaken only in the setting of a clinical trial.
The rate of breakthrough Candida infections in this study appears similar to that reported with fluconazole 20 with a shift towards more resistant species. It is interesting that plasma steady-state trough voriconazole levels around the time the infection occurred were o0.2, o0.2, 0.33, 0.55, 0.63 and 1.78 mg/ml in the six candidiasis cases ( Table 2 ). The lack of occurrence of breakthrough candidiasis in patients with drug levels of 42 mg/ml appears to be statistically significant. Of course, it should be noted that the interval between obtaining drug level and diagnosis of a fungal infection exceeded 4 weeks in two Candida cases and one mucor case. Likewise, as the diagnosis of Candida infection was determined from broncho-alveolar lavage in 5/6 patients, the possibility of colonization or contamination cannot be ruled out. This is not unexpected considering the retrospective nature of the study.
Analysis of data for 249 patients from six phase III clinical trials of voriconazole has demonstrated a significant correlation between drug levels and end-of-treatment outcome assessment. 21 Using MIC data for voriconazole in over 8000 clinical isolates, the Antifungal Susceptibility Subcommittee of the Clinical and Laboratory Standards Institute has now proposed interpretive breakpoints for voriconazole and Candida species. 22 These are as follows: o1 mg/ml susceptible, 2 mg/ml susceptible dose dependent, and 44 mg/ml resistant. Although the majority of C glabrata isolates were susceptible to voriconazole, among the fluconazole-resistant isolates, 44% were susceptible to voriconazole in a dose-dependent manner (MIC 2 mg/ml). Such organisms would require higher plasma concentrations to eradicate infection.
Previously published data suggest that drug levels can affect outcome of antifungal therapy in clinical practice. The maximum amount of information is available for itraconazole showing that blood levels of itraconazole exceeding a threshold are needed to reduce the risk of Aspergillus infections. [23] [24] [25] Data on file at the United States Food and Drug Administration show that success rate in patients with fungal infections, whose mean voriconazole plasma levels were o0.5 g/ml, was 46% compared to 56% with mean plasma levels 40.5 g/ml.
21 A recent study 9 reported a significant association between higher plasma voriconazole levels and therapeutic success in patients with documented Aspergillus infection. Favorable responses were observed in 10 of 10 patients with drug concentrations 42.05 mg/ml and in 10 of 18 patients with concentrations o2.05 mg/ml (P ¼ 0.014).
While our observation does seem to be compelling in combination with the above data, the lack of aspergillosis Voriconazole after allogeneic HSCT S Trifilio et al in patients with low voriconazole levels in this series would seem to weaken the case for a relationship between drug levels and outcome. One possible explanation is that the incidence of aspergillosis in our patient population is not high enough to have this modest-sized series show a difference in outcome between patients with low and optimum drug levels. This study, our previous observations of large interpatient variability in plasma voriconazole levels, 11 and other data 9 are insufficient to recommend starting routine therapeutic drug monitoring in all patients on voriconazole. However, we feel that future prospective clinical trials of voriconazole should incorporate therapeutic drug monitoring. Consideration should be given to checking drug levels in patients who are being treated with the drug for confirmed aspergillosis, and in those who develop breakthrough infections with Candida or Aspergillus species while on the drug.
We conclude that voriconazole is effective at preventing aspergillosis. Breakthrough zygomycosis is a potential problem in a small number of patients treated with voriconazole (or itraconazole followed by voriconazole) for a prolonged period of time. Breakthrough infections with organisms susceptible to voriconazole in a dosedependent manner may occur in patients with low trough levels suggesting that the role of therapeutic drug monitoring needs to be explored prospectively.
